Source: BioSpace
Area: News
According to BioSpace, the MHRA has approved Iluvien® (intravitreal insert releasing fluocinolone acetonide for up to 36 months) for the treatment of vision impairment associated with chronic diabetic macular oedema considered insufficiently responsive to available therapies.
This marketing authorisation follows the recently announced approval in Austria. These approvals were preceded by completion of the Decentralized Regulatory Procedure (DCP) in the EU, in which the MHRA, serving as the Reference Member State (RMS), delivered a positive outcome for Iluvien® along with six Concerned Members States, specifically (Read more...)
Uncategorized